Teva Buying Mylan? “Not Likely,” Abbott CEO Says
This article was originally published in The Pink Sheet Daily
Abbott CEO Miles White stands by his assertion that a combination between Mylan and OTC drug maker Perrigo makes more strategic sense than a combination between Myaln and Teva. Abbott is Mylan’s largest shareholder with a 14.23% stake.
Register for our free email digests: